Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Buy
53
MDXH Quote, Financials, Valuation and Earnings
Last price:
$2.2500
Seasonality move
:
-21.37%
Day range:
$2.1000 - $2.2500
52-week range:
$1.5500 - $4.6400
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.86x
P/B ratio:
6.52x
Volume:
22.3K
Avg. volume:
163.7K
1-year change:
-45.1%
Market cap:
$110.9M
Revenue:
$70.2M
EPS (TTM):
-$1.52
Analysts' Opinion
-
Consensus RatingMDxHealth SA has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, MDxHealth SA has an estimated upside of 169.64% from its current price of $2.2400.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.2400.
Fair Value
-
According to the consensus of 4 analysts, MDxHealth SA has 169.64% upside to fair value with a price target of -- per share.
MDXH vs. S&P 500
-
Over the past 5 trading days, MDxHealth SA has overperformed the S&P 500 by 1.87% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MDxHealth SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MDxHealth SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MDxHealth SA reported revenues of $23.3M.
Earnings Growth
-
MDxHealth SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MDxHealth SA reported earnings per share of -$0.40.
Enterprise value:
113M
EV / Invested capital:
1.65x
Price / LTM sales:
0.86x
EV / EBIT:
--
EV / Revenue:
1.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$52.3M
Return On Assets:
-31.08%
Net Income Margin (TTM):
-49.52%
Return On Equity:
-650.14%
Return On Invested Capital:
-85.88%
Operating Margin:
-26.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $30.2M | $63.7M | $84.7M | $19.4M | $23.3M | |
| Gross Profit | $14.8M | $38.5M | $52.3M | $12.6M | $14.3M | |
| Operating Income | -$36.4M | -$30.5M | -$25.8M | -$4.6M | -$6.1M | |
| EBITDA | -$33M | -$28.7M | -$32.1M | -$2.1M | -$3.7M | |
| Diluted EPS | -$2.58 | -$2.06 | -$1.52 | -$0.37 | -$0.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $40.9M | $45.6M | $70.2M | |
| Total Assets | -- | -- | $122.6M | $135.7M | $157.4M | |
| Current Liabilities | -- | -- | $19.3M | $18.8M | $45.5M | |
| Total Liabilities | -- | -- | $101.1M | $117.9M | $140.4M | |
| Total Equity | -- | -- | $21.5M | $17.8M | $17M | |
| Total Debt | -- | -- | $35.3M | $36M | $51.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$23.8M | -$22.8M | -$4.3M | -$5.6M | |
| Cash From Investing | -- | -$6.3M | -$2.1M | -$439K | -$13K | |
| Cash From Financing | -- | $34.5M | $41.4M | -$2.3M | $33.6M | |
| Free Cash Flow | -- | -$30.6M | -$25.8M | -$5.1M | -$5.8M | |
MDXH
Sector
Market Cap
$110.9M
$46.5M
Price % of 52-Week High
48.28%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
-40.99%
-0.6%
1-Year Price Total Return
-45.1%
-31.38%
Beta (5-Year)
-390,599.621
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.2463
200-day SMA
Sell
Level
$2.4888
Bollinger Bands (100)
Sell
Level
1.8921 - 2.7121
Chaikin Money Flow
Sell
Level
-1.9M
20-day SMA
Buy
Level
$2.1795
Relative Strength Index (RSI14)
Buy
Level
55.2721
ADX Line
Buy
Level
13.6392
Williams %R
Neutral
Level
-46.6667
50-day SMA
Buy
Level
$2.0330
MACD (12, 26)
Buy
Level
0.0644
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Sell
Level
-805.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.3063)
Sell
CA Score
(Annual)
Level (-3.5959)
Buy
Beneish M-Score
(Annual)
Level (-2.8713)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.3952)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
Stock Forecast FAQ
In the current month, MDXH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MDXH average analyst price target in the past 3 months is --.
-
Where Will MDxHealth SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that MDxHealth SA share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About MDxHealth SA?
Analysts are divided on their view about MDxHealth SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MDxHealth SA is a Sell and believe this share price will drop from its current level to --.
-
What Is MDxHealth SA's Price Target?
The price target for MDxHealth SA over the next 1-year time period is forecast to be -- according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MDXH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MDxHealth SA is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDXH?
You can purchase shares of MDxHealth SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MDxHealth SA shares.
-
What Is The MDxHealth SA Share Price Today?
MDxHealth SA was last trading at $2.2500 per share. This represents the most recent stock quote for MDxHealth SA. Yesterday, MDxHealth SA closed at $2.2400 per share.
-
How To Buy MDxHealth SA Stock Online?
In order to purchase MDxHealth SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 9.06% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 1.68% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.33% over the past day.
